Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma.
D000328:Adult; D000368:Aged; D000577:Amides; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D010879:Piperazines / Q000008:administration & dosage*; D011720:Pyrazoles; D011929:Razoxane / Q000008:administration & dosage* / Q000009:adverse effects; D012263:Ribonucleosides / Q000008:administration & dosage* / Q000009:adverse effects; D012266:Ribose
D000577:Amides; D000970:Antineoplastic Agents; D010879:Piperazines; D011720:Pyrazoles; D012263:Ribonucleosides; C002997:pyrazofurin; D011929:Razoxane; D012266:Ribose